To test this hypothesis, we genotyped the putatively functional polymorphisms in the NOXA and MCL1 promoters, and aimed to determine whether these genetic variants can, independently or jointly with HPV16 seropositivity, influence the risk of SCCHN, especially for those arising at the oropharyngeal site. Here, MCL1 is linked to head and neck squamous cell carcinoma.